These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 2676640)

  • 1. CA 125 levels in endometriosis patients before, during and after treatment with danazol or LHRH agonists.
    Acien P; Shaw RW; Irvine L; Burford G; Gardner R
    Eur J Obstet Gynecol Reprod Biol; 1989 Sep; 32(3):241-6. PubMed ID: 2676640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CA 125 antigen is an effective diagnostic for external endometriosis.
    Takahashi K; Yamane Y; Kijima S; Yoshino K; Shibukawa T; Kitao M
    Gynecol Obstet Invest; 1987; 23(4):257-60. PubMed ID: 3475234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiendometrial antibodies in endometriosis measured by an enzyme-linked immunosorbent assay before and after treatment with danazol and nafarelin.
    Kennedy SH; Starkey PM; Sargent IL; Hicks BR; Barlow DH
    Obstet Gynecol; 1990 Jun; 75(6):914-8. PubMed ID: 2140439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum CA-125 levels in women with endometriosis.
    Fraser IS; McCarron G; Markham R
    Aust N Z J Obstet Gynaecol; 1989 Nov; 29(4):416-20. PubMed ID: 2534343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum CA-125 and 17 beta-estradiol in patients with external endometriosis on danazol.
    Takahashi K; Musa AA; Nagata H; Kitao M
    Gynecol Obstet Invest; 1990; 29(4):301-4. PubMed ID: 2361639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the origin and significance of serum CA-125 concentrations in 97 patients with endometriosis before, during, and after buserelin acetate, nafarelin, or danazol.
    Franssen AM; van der Heijden PF; Thomas CM; Doesburg WH; Willemsen WN; Rolland R
    Fertil Steril; 1992 May; 57(5):974-9. PubMed ID: 1533376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormonal effects of danazol and medical oophorectomy in endometriosis.
    Meldrum DR; Pardridge WM; Karow WG; Rivier J; Vale W; Judd HL
    Obstet Gynecol; 1983 Oct; 62(4):480-5. PubMed ID: 6350956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nafarelin versus danazol in the treatment of endometriosis.
    Rolland R; van der Heijden PF
    Am J Obstet Gynecol; 1990 Feb; 162(2):586-8. PubMed ID: 2137976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Placebo-controlled study on serum concentrations of CA-125 before and after treatment of endometriosis with danazol or high-dose medroxyprogesterone acetate alone or after surgery.
    Kauppila A; Telimaa S; Rönnberg L; Vuori J
    Fertil Steril; 1988 Jan; 49(1):37-41. PubMed ID: 2961624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CA-125 is an effective marker for patients with external endometriosis and on danazol: case reports.
    Takahashi K; Yoshino K; Nagata H; Kusakari M; Kitao M
    Fertil Steril; 1988 Jul; 50(1):173-5. PubMed ID: 3164281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of nafarelin acetate and danazol in the treatment of endometriosis.
    Kennedy SH; Williams IA; Brodribb J; Barlow DH; Shaw RW
    Fertil Steril; 1990 Jun; 53(6):998-1003. PubMed ID: 2140996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic changes during medical treatment of endometriosis: nafarelin acetate versus danazol.
    Burry KA; Patton PE; Illingworth DR
    Am J Obstet Gynecol; 1989 Jun; 160(6):1454-9; discussion 1459-61. PubMed ID: 2525337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of the oncofetal antigens CA-125, CA 19-9 and CA 15-3 in patients with endometriosis.
    Panidis D; Vlassis G; Matalliotakis J; Skiadopoulos S; Kalogeropoulos A
    J Endocrinol Invest; 1988 Dec; 11(11):801-4. PubMed ID: 3225401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolactin and its response to the luteinizing hormone-releasing hormone thyrotropin-releasing hormone test in patients with endometriosis before, during, and after treatment with danazol.
    Acién P; Lloret M; Graells M
    Fertil Steril; 1989 May; 51(5):774-80. PubMed ID: 2651165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Danazol and prolactin status in patients with endometriosis.
    Wallace AM; Lees DA; Roberts AD; Gray CE; McLaren EH; Low RA
    Acta Endocrinol (Copenh); 1984 Dec; 107(4):445-9. PubMed ID: 6440389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of a luteinizing hormone releasing hormone (LRH) agonist (Wy-40,972), levonorgestrel, danazol and ovariectomy on experimental endometriosis in the rat.
    Jones RC
    Acta Endocrinol (Copenh); 1984 Jun; 106(2):282-8. PubMed ID: 6428124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with a luteinising hormone-releasing hormone analogue (Buserelin) in danazol-resistant endometriosis patients.
    Franssen AM; Rolland R; Chadha DR; Willemsen WN; Vemer HM
    Eur J Obstet Gynecol Reprod Biol; 1986 Dec; 23(5-6):379-86. PubMed ID: 3100357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cortical and trabecular bone mineral content in women with endometriosis: effect of gonadotropin-releasing hormone agonist and danazol.
    Dawood MY; Lewis V; Ramos J
    Fertil Steril; 1989 Jul; 52(1):21-6. PubMed ID: 2501109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotropin-releasing hormone agonists or danazol.
    Tummon IS; Ali A; Pepping ME; Radwanska E; Binor Z; Dmowski WP
    Fertil Steril; 1988 May; 49(5):792-6. PubMed ID: 3129312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of LHRH agonist therapy in the treatment of endometriosis (English experience).
    Jelley RY; Magill PJ
    Prog Clin Biol Res; 1986; 225():227-38. PubMed ID: 3097668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.